KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone857-999-0075
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.39 million
Profitability
Miscellaneous
Employees33
OptionableNot Optionable
Kalvista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions
What is Kalvista Pharmaceuticals' stock symbol?
Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."
How were Kalvista Pharmaceuticals' earnings last quarter?
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) released its quarterly earnings results on Friday, December, 14th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.24. The specialty pharmaceutical company had revenue of $5.59 million for the quarter, compared to analysts' expectations of $3.70 million. Kalvista Pharmaceuticals had a negative return on equity of 29.46% and a negative net margin of 84.47%. View Kalvista Pharmaceuticals' Earnings History.
When is Kalvista Pharmaceuticals' next earnings date?
What price target have analysts set for KALV?
5 analysts have issued 1 year price objectives for Kalvista Pharmaceuticals' shares. Their predictions range from $20.00 to $32.00. On average, they expect Kalvista Pharmaceuticals' share price to reach $27.3333 in the next twelve months. This suggests a possible upside of 57.2% from the stock's current price. View Analyst Price Targets for Kalvista Pharmaceuticals.
What is the consensus analysts' recommendation for Kalvista Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kalvista Pharmaceuticals.
What are Wall Street analysts saying about Kalvista Pharmaceuticals stock?
Here are some recent quotes from research analysts about Kalvista Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States. " (1/2/2019)
- 2. BTIG Research analysts commented, "Another Beat-and-Raise; Reiterate Buy and $260 PT TMO kicked off 2018 on a strong note, with 7% organic revenue growth (against 4% growth in 1Q17) and 20% EPS growth (upside from guidance largely driven by higher organic growth, and less so from more favorable FX), handily beating consensus expectations. Full year guidance was raised: 1) on the top, to reflect (roughly in equal parts of) better organic revenue growth (5% from 4-5% prior), greater Patheon acquisition contribution, and more favorable FX; and 2) on the bottom, stronger 1Q operational performance and more favorable FX, partially offset by small dilution from a recent bolt-on. Strong performance was broad-based, although standouts in the quarter include the biopharma customer segment (+10% y/y), China (high-teens growth), and Analytical Instruments (+13% organic growth; strength across FEI, chromatography / MS, chemical analysis). While TMO has a strong financial performance track record, we think the company is currently better positioned than ever to capitalize on a relatively strong end market environment (e.g., biopharma, industrial) and take market share to drive top line growth, continue to execute on operational efficiency (e.g., Patheon acquisition synergy targets tracking ahead of expectations), and maximize capital deployment opportunities (3.8x leverage ratio at quarter-end vs. 3.75x estimated year-end average; ~$500mm share buyback targeted for 2H; active M&A pipeline; rising interest rates already factored into longer-term forecasts and strategic planning). Our PT gets valuation closer to the peer average on a forward P/E basis." (4/29/2018)
Has Kalvista Pharmaceuticals been receiving favorable news coverage?
Media coverage about KALV stock has trended somewhat positive on Friday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kalvista Pharmaceuticals earned a coverage optimism score of 1.6 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of Kalvista Pharmaceuticals' key competitors?
Some companies that are related to Kalvista Pharmaceuticals include Wave Life Sciences (WVE), Myovant Sciences (MYOV), TherapeuticsMD (TXMD), Clovis Oncology (CLVS), Uniqure (QURE), Esperion Therapeutics (ESPR), Kiniksa Pharmaceuticals (KNSA), Spectrum Pharmaceuticals (SPPI), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), Puma Biotechnology (PBYI), Tricida (TCDA), Retrophin (RTRX) and Homology Medicines (FIXX).
Who are Kalvista Pharmaceuticals' key executives?
Kalvista Pharmaceuticals' management team includes the folowing people:
- Mr. Thomas Andrew Crockett, Chief Exec. Officer and Director (Age 43)
- Mr. Benjamin L. Palleiko, Chief Financial Officer (Age 52)
- Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 55)
- Mr. John B. McKune, VP of Fin. (Age 42)
- Dr. Edward P. Feener Ph.D., Chief Scientific Officer (Age 58)
How do I buy shares of Kalvista Pharmaceuticals?
Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kalvista Pharmaceuticals' stock price today?
One share of KALV stock can currently be purchased for approximately $17.39.
How big of a company is Kalvista Pharmaceuticals?
Kalvista Pharmaceuticals has a market capitalization of $325.57 million and generates $8.39 million in revenue each year. The specialty pharmaceutical company earns $-15,800,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.
What is Kalvista Pharmaceuticals' official website?
How can I contact Kalvista Pharmaceuticals?
Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]
MarketBeat Community Rating for Kalvista Pharmaceuticals (NASDAQ KALV)
MarketBeat's community ratings are surveys of what our community members think about Kalvista Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALV will underperform the S&P 500 over the long term. You may vote once every thirty days.
